MedTrace Logo

Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

NCT02571972 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-12-03

Study results available
· View outcomes & findings →

Summary

This study seeks to evaluate the effect of topical aqueous suppression on the anatomic and functional response to intravitreal anti-vascular endothelial growth factor (VEGF) injections in non-responders with wet age-related macular degeneration.

Conditions

Interventions

DRUG

Dorzolamide-timolol

On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration

Sponsors & Collaborators

  • J. Arch McNamara Research Fund

    collaborator OTHER

  • Mid Atlantic Retina

    collaborator OTHER

  • Wills Eye

    lead OTHER

Principal Investigators

  • Jason Hsu, MD · Wills Eye Hospital, Mid Atlantic Retina

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-01
Primary Completion
2015-09-30
Completion
2015-12-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02571972 on ClinicalTrials.gov